By a News Reporter-Staff News Editor at Pharma Business Week — According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Oncogenex Pharmaceuticals, Inc. (Form 424B5) was posted on June 27, 2014.
The SIC code for this company is 2835, In Vitro and In Vivo Diagnostic Substances.
There were 5 documents filed with this form. The SEC file number is 0001193125-14-253322.
The contact information for this company is 1522 217TH PLACE S.E., BOTHELL WA 98021, 4254879500.
Our editors provided additional information about Form 424B5: Prospectus filed pursuant to Rule 424(b)(5).
A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.
For additional information on this SEC filing see: http://www.sec.gov/Archives/edgar/data/949858/0001193125-14-253322-index.html.
Keywords for this news article include: Oncogenex Pharmaceuticals Inc., Pharmaceutical Company, SEC Filing, In Vitro and In Vivo Diagnostic Substances.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Oncogenex Pharmaceuticals, Inc. Files SEC Form 424B5, Prospectus [Rule 424(B)(5)] (Jun. 27, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission
- 1 min Read
- 07.9.2014
Why distillate crack spreads will likely experience more volatility.
When people talk about interest rates, real estate prices, and cyclical and secular trends, there’s one piece of context they tend not to mention.
The saying that there is no such thing as a free lunch is very much true for Robinhood.
Another Black Swan event is taking place right now. And it’s likely to have a similar effect on uranium prices.
A weekly five-point roundup of critical events in fintech, the future of finance and the next wave of banking industry transformation.
Of course, I couldn’t envision the extent to which AI would take off when I initially urged you to buy Nvidia.
